RTI Surgical Reports 2Q16 Revenue
ORTHOWORLD estimates RTI Surgical (RTIX) 2Q16 orthopaedic revenue of US $56.0MM, +1.1% from 2Q15, as reported.
ORTHOWORLD estimates 2Q16 segment sales and growth on an as-reported basis, as follows.
- Trauma $12.4MM, -5.5%
- Spine $20.9MM, +4.1%
- Orthobiologics $22.7MM, +2.2%
Leadership noted that U.S. direct spine sales of $17.6MM grew +25% vs. 2Q15, with record revenue for map3 Allograft and nanOss Advanced Bone Graft Substitute, as well as double-digit direct spine hardware sales. map3 Allograft revenue more than tripled in sales for 2Q16 vs. 2Q15.
During 2Q16, RTIX announced launch of the Release Laminoplasty Fixation System, as well as deformity instrumentation for the Streamline TL Spinal Fixation System.
U.S. direct sports and orthopaedic segment revenue dropped by -2%, attributed to revenue pressure from a continued move to autograft within accounts.
Globally, commercial revenue decreased due to lower orders from certain distributors, primarily in spine, trauma and dental.
RTIX announced its first peer-reviewed published pre-clinical study comparing multipotent adult progenitor cells (MAPCs) to mesenchymal stem cells (MSCs) in bone healing. Results suggest that MAPCs, such as the technology used in map3 Cellular Allogeneic Bone Grafts, exhibited a more robust angiogenic protein release profile vs. MSCs in vitro.
Finally, leadership noted that RTIX will perform a comprehensive strategic review of all business lines and operations to determine how to adapt to changing industry and healthcare paradigms. (No timetable has been set for completion of the review, and there is no assurance that any specific actions will result from it.)
Sources: RTI Surgical, Inc.; ORTHOWORLD Inc.